Beatrice Nolan

Beatrice Nolan

Auto-generated profile, based on publicly available information

Beatrice Nolan

Children’s Health Ireland at Crumlin, Dublin, Ireland

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2013 in Blood
Verified
Journal Article
Open access
PDF file
SGSamantha C. Gouw
Samantha C. Gouw
HBH. Marijke van Den Berg
H. Marijke van Den Berg
KFKathelijn Fischer
Kathelijn Fischer
GAGünter Auerswald
Günter Auerswald
MCManuel Carcao
Manuel Carcao
JBJohanna (Anske) Gerarda van der Bom
Johanna (Anske) Gerarda van der Bom
The objective of this study was to examine the association of the intensity of treatment, ranging from high-dose intensive factor VIII (FVIII) treatment to prophylactic treatment, with the inhibitor incidence among previously untreated patients with severe hemophilia A. This cohort study aimed to include consecutive patients with a FVIII activity < 0.01 IU/mL, born between 2000 and 2010, and observed during their first 75 FVIII exposure days. Intensive FVIII treatment of hemorrhages or surgery at the start of treatment was associated with an increased inhibitor risk (adjusted hazard ratio [aHR], 2.0; 95% confidence interval [CI], 1.3-3.0). High-dose FVIII treatment was associated with a higher inhibitor risk than low-dose FVIII treatment (aHR, 2.3; 95% CI, 1.0-4.8). Prophylaxis was only associated with a decreased overall inhibitor incidence after 20 exposure days of FVIII. The association with prophylaxis was more pronounced in patients with low-risk F8 genotypes than in patients with high-risk F8 genotypes (aHR, 0.61, 95% CI, 0.19-2.0 and aHR, 0.85, 95% CI, 0.51-1.4, respectively). In conclusion, our findings suggest that in previously untreated patients with severe hemophilia A, high-dosed intensive FVIII treatment increases inhibitor risk and prophylactic FVIII treatment decreases inhibitor risk, especially in patients with low-risk F8 mutations.

23 April 2015 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
GYG. Young
G. Young
JMJ. Mahlangu
J. Mahlangu
RKR. Kulkarni
R. Kulkarni
BNB. Nolan
B. Nolan
RLR. Liesner
R. Liesner
GAG. Allen
G. Allen
Background Prophylactic factor replacement, which prevents hemarthroses and thereby reduces the musculoskeletal disease burden in children with hemophilia A, requires frequent intravenous infusions (three to four times weekly). Objective Kids A‐LONG was a phase 3 open‐label study evaluating the safety, efficacy and pharmacokinetics of a longer‐acting factor, recombinant factor VIII Fc fusion protein (rFVIIIFc), in previously treated children with severe hemophilia A (endogenous FVIII level of < 1 IU dL−1 [< 1%]). Methods The study enrolled 71 subjects. The starting rFVIIIFc regimen was twice‐weekly prophylaxis (Day 1, 25 IU kg−1; Day 4, 50 IU kg−1); dose (≤ 80 IU kg−1) and dosing interval (≥ 2 days) were adjusted as needed. A subset of subjects had sequential pharmacokinetic evaluations of FVIII and rFVIIIFc. The primary endpoint was development of inhibitors (neutralizing antibodies). Secondary endpoints included pharmacokinetics, annualized bleeding rate (ABR), and number of infusions required to control a bleed. Results No subject developed an inhibitor to rFVIIIFc. Adverse events were typical of a pediatric hemophilic population. The rFVIIIFc half‐life was prolonged relative to that of FVIII, consistent with observations in adults and adolescents. The median ABR was 1.96 overall, and 0.00 for spontaneous bleeds; 46.4% of subjects reported no bleeding episodes on study. Ninety‐three per cent of bleeding episodes were controlled with one to two infusions. The median average weekly rFVIIIFc prophylactic dose was 88.11 IU kg−1. At study end, 62 of 69 subjects (90%) were infusing twice weekly. Among subjects who had been previously receiving FVIII prophylaxis, 74% reduced their dosing frequency with rFVIIIFc. Conclusion Twice‐weekly infusions with rFVIIIFc were well tolerated and yielded low bleeding rates in children with severe hemophilia A.

9 January 2020 in Haematologica
Verified
Journal Article
Open access
PDF file
CMChristoph Male
Christoph Male
NANadine G. Andersson
Nadine G. Andersson
ARAnne Rafowicz
Anne Rafowicz
RLRi Liesner
Ri Liesner
KKKarin Kurnik
Karin Kurnik
MBMarijke Van Den Berg
Marijke Van Den Berg
The incidence of FIX inhibitors in severe hemophilia B (SHB) is not well defined. Frequencies of 3-5% have been reported but most studies to date were small, including patients with different severities, and without prospective follow-up for inhibitor incidence. Study objective was to investigate inhibitor incidence in patients with SHB followed up to 500 exposure days (ED), the frequency of allergic reactions, and the relationship with genotypes. Consecutive previously untreated patients (PUPs) with SHB enrolled into the PedNet cohort were included. Detailed data was collected for the first 50 ED, followed by annual collection of inhibitor status and allergic reactions. Presence of inhibitors was defined by at least two consecutive positive samples. Additionally, data on factor IX gene mutation was collected. 154 PUPs with SHB were included; 75% were followed until 75 ED, and 43% until 500 ED. Inhibitors developed in 14 patients (7 high-titre). Median number of ED at inhibitor manifestation was 11 (IQR 6.5-36.5). Cumulative inhibitor incidence was 9.3% (95%CI 4.4-14.1) at 75 ED, and 10.2% (5.1-15.3) at 500 ED. Allergic reactions occurred in 4 (28.6%) inhibitor patients. Missense mutations were most frequent (46.8%) overall but not associated with inhibitors. Nonsense mutations and deletions with large structural changes comprised all mutations among inhibitor patients and were associated with an inhibitor risk of 26.9% and 33.3%, respectively. In an unselected, well-defined cohort of PUPs with SHB, cumulative inhibitor incidence was 10.2% at 500 ED. Nonsense mutations and large deletions were strongly associated with the risk of inhibitor development. The PedNet Registry is registered at clinicaltrials.gov; identifier: NCT02979119

29 April 2019 in Haemophilia
Verified
Journal Article
Open access
PDF file
MCManuel Carcao
Manuel Carcao
CECarmen Escuriola‐Ettingshausen
Carmen Escuriola‐Ettingshausen
ESElena Santagostino
Elena Santagostino
JOJohannes Oldenburg
Johannes Oldenburg
RLRi Liesner
Ri Liesner
FGFuture of Immunotolerance Treatment Group
Future of Immunotolerance Treatment Group
Introduction: As a result of the new treatment paradigm that the haemophilia community will face with the availability of novel (non‐factor) therapies, an updated consensus on ITI recommendations and inhibitor management strategies is needed.Aim: The Future of Immunotolerance Treatment (FIT) group was established to contemplate, determine and recommend the best management options for patients with haemophilia A and inhibitors.Discussion and Conclusions: Despite the considerable success of emicizumab in the management of inhibitor patients, the FIT group still sees the importance of eradicating inhibitors. However, the availability of emicizumab and other non‐factor therapies in the future might impact greatly on how ITI is undertaken. Theoretically, concomitant use of emicizumab and FVIII might allow emicizumab to effectively prevent bleeding with lower dose ITI regimens. This might allow for the greater adoption of low‐dose/low‐frequency FVIII ITI regimens, which may result in a reduced need for central venous access devices while still maintaining a reasonable likelihood of ITI success. The FIT group proposes a new management algorithm for current ITI (without emicizumab) and a hypothetical new approach with the availability of emicizumab. As there are no published data regarding the concomitant use of emicizumab and FVIII for ITI, the FIT Expert group encourages the undertaking of properly conducted prospective studies to explore these approaches further.

1 February 2017 in The Lancet Haematology
Verified
Journal Article
Closed access
KFKathelijn Fischer
Kathelijn Fischer
RKRoshni Kulkarni
Roshni Kulkarni
BNBeatrice Nolan
Beatrice Nolan
JMJohnny Mahlangu
Johnny Mahlangu
SRSavita Rangarajan
Savita Rangarajan
GAGeoffrey Allen
Geoffrey Allen

12 July 2017 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
NANadine G. Andersson
Nadine G. Andersson
GAGünter Auerswald
Günter Auerswald
CBChris Barnes
Chris Barnes
MCManuel Carcao
Manuel Carcao
ADAmy L. Dunn
Amy L. Dunn
RLRolf Ljung
Rolf Ljung